Pronova Hopes Rx Omega-3 Success Translates To Supplements
This article was originally published in The Tan Sheet
Executive Summary
Pronova BioPharma ASA has the capabilities necessary to become “a major player in the new supplement market,” CEO Morten Jurs said. The Norwegian firm likely will spend $10 million to adjust its plant to manufacture consumer products and plans to enter the supplement market in the second half of 2012.